Amanda Moore has nearly 20 years of clinical operations and development experience in the biotechnology and pharmaceutical industry with a track record of leading innovation in clinical trials, pioneering operating committee relationships, and oversight of global development programs. Ms Moore joined Abeona in October 2020, holding positions of increasing responsibility, and most recently served as Senior Director, Head of Program Leadership. Previously, she has served in clinical operations and development roles with Biogen, Reckitt Benckiser, Sage Therapeutics and Intercell. Ms Moore holds a master’s degree in Health Science from the George Washington University.

Kurt Lumsden is the VP Study Operations at Hawthorne Effect, Inc. responsible for delivery of services to clients. He has over 30 years’ experience in Healthcare and Clinical research including roles at sites, sponsors, and eClinical solution providers and Clinical Research Organizations. Additionally, and is an expert in Decentralized Clinical Trials, phases I-IV and global services (North America; LATAM; EU; APAC; Africa) across multiple therapeutic area, including pharmaceutical and medical device trials. Mr Lumsden obtained an MBA from City University, a BS in Perfusion Technology from Rush University, a BA in Healthcare Leadership from National-Louis University and is a Registered Nurse with broad clinical experience obtained at healthcare organizations in the US and UK, including Intensive Care, Operating Room, Behavioral Health and Home Care services. He has held previous positions with Fortrea, Labcorp, GlobalCare Clinical Trials, Parexel and ClinPhone.

Alba Córdoba, PhD oversees Technology Transfer and Business Development activities at Nanomol Technologies, where she heads scale-up, engineering, IPR and business development activities. Since 2017 she has been leading the DELOS nanoformulation unit of the company, defining and implementing the strategic plan for business consolidation & growth of the company, bringing this novel nanoparticle technology up to the GMP pilot manufacturing and securing several contract pharmaceutical development projects for pharma & biotech. Dr Córdoba garners 15-plus years of experience in R&D and technology transfer projects for pharma, biotech and chemical companies, in the fields of drug delivery, biomaterials, formulation, nanoparticles and nanomedicine, mainly in small biotech companies working closely with both global and small pharma and biotech partners and customers. She is Chemical Engineer from the Polytechnic University of Catalonia, Postgraduate in Tech Transfer and Innovation Management and holds a PhD in Chemical Science and Technology.

Dr Engelhardt is Co-Founder and CEO of Kano Therapeutics, a biotech startup enabling cell and gene therapies based in Cambridge, MA. She holds a PhD in Biophysics from the Technical University of Munich, with a focus on DNA nanotechnology and started the company based on her postdoctoral research work in Mark Bathe’s BatheBioNano lab at MIT. She was awarded with MIT’s 2020 Innovative Woman in Entrepreneurship Award, Activate Global fellowship, Pillar VCs Founder to watch in Biotech Award 2021, and most recently the Termeer Fellowship for first-time CEOs.

Joan Melé, Chief Commercial Officer at Dara Pharma, with Technical Background as Engineer together with master’s in marketing & Sales.

With a working experience of more than 20 years on International Sales Management & business development for Fill and Finish Machinery and Pharmaceutical Process Equipment, has been managing specific market requests in Asia, Middle East, Latin American, North American, Russia and Europe.

Directly involved on Key Accounts needs for Pharmaceutical Process Equipment in a B-to-B market and multilateral agreements between OEM, Devices Manufacturer’s, CDMO and Pharma Industry.

Michele Guasti is Global Product Manager at the Pharmaceutical Solutions Division of Terumo Medical Care Solutions. He graduated from the University of Brescia (Italy) and holds a Master’s degree in Mechanical Engineering. Mr Guasti has more than nine years of experience in primary packaging within the pharmaceutical industry. In the last five years, he has acquired expertise in fill-finish processes for injectable drugs and associated technologies.

Mr Guasti has extensive experience in establishing strong partnerships and collaborations between companies and supporting pharma customers in finding solutions to their daily challenges. Previously, he worked in strategic product management at Stevanato Group.

Armon Sharei, PhD, is the Founder and CEO of Portal Biotechnologies, a cell engineering platform company enabling next generation cell engineering and cell analytics across research and clinical applications. The company is implementing a simplified intracellular delivery approach, focused on accelerating advances enabled by the new generation of RNA, gene editing, and molecular design technologies. Armon was previously founder and CEO of SQZ Biotech and led the company from invention to post-IPO with over $300M in equity financing, a $1Bn Roche collaboration and three clinical trials. Armon received his BS in Chemical Engineering from Stanford and his PhD in Chemical Engineering from MIT in the labs of Klavs Jensen and Robert Langer. Dr Sharei has authored 20+ peer-reviewed publications and is the inventor on 20+ patent families. He has been recognized in INC. Magazine’s 30 under 30, Endpoints 40 under 40, and Forbes Magazine’s 30 under 30 in Healthcare.

Vince Masciopinto is currently a Customer Solutions Director at SHL Medical, where he is responsible for supporting pharma and biotech customers in the adoption of customized, complex, and bespoke solutions. Vince works closely with business development, product management, and other teams to guide customers in selecting the right drug delivery solution. He brings with him decades of experience in the healthcare industry, having previously worked at companies like Eitan Medical and West Pharmaceutical Services.

S Chakra Chennubhotla, PhD earned his PhD from the Department of Computer Science at the University of Toronto specializing in computer vision, machine learning and AI. Dr Chennubhotla was tenured Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh.

Dr Chennubhotla co-founded SpIntellx to actualize the translational potential of these Pitt IP-fueled platforms. Dr Chennubhotla’s experience encompasses years in both industry and academia. He was the lead PI on several National Institutes of Health and National Science Foundation grants covering broad areas of bioimaging, molecular biophysics, computational and systems biology, and spatial intratumor heterogeneity. He holds several patents and has published extensively, appearing in Science Translational Medicine and Nature Communications, among other prominent journals.

Delfi Krishna, PhD, MBA joined Immatics in Jan 2021 and is responsible for late-stage development of cell therapies. Dr Krishna has nearly 20 years of experience from discovery to commercialization across 15 biologics and 11 different cell therapies. During her PhD at Georgia Institute of Technology, she designed efficient and targeted retroviral and lentiviral vectors for gene delivery in human cells. After she completed her post doctorate, she worked at GlaxoSmithKline in biologics and cell therapy development. She led large matrix teams to deliver process, product strategy and regulatory submissions for several monoclonal antibodies, domain antibodies and antibody drug conjugates. She executed strategies to reduce cost and increase speed and agility in all phases of development from pre-clinical, through clinical proof of concept, launch and post launch. She designed and delivered technology, portfolio, organizational and talent strategy for the cell therapy business unit. In her current role at Immatics she leads a cross functional medicine development team to bring autologous cell therapies to market. She has recently completed her MBA from MIT Sloan School of Management. Her leadership mission is to inspire colleagues to join her in bringing innovative medicines to patients and while they do so, to help them find their highest potential, their most confidence voice and have loads of fun while we break boundaries together. In her free time, she likes to run science experiments with her daughter and dream about doing T-cell experiments aboard the international space station.

Darren Quinn is the Head of Business Development at BDD Pharma where he leads the global business development and licensing activities.

Darren earned a master’s degree in chemistry from the University of Strathclyde in Glasgow, Scotland, where his industry experience began with a placement as an Organic Chemist at Technologie Servier. He furthered his career at Lonza and Next Pharma, where he specialized in oral solid dosage (OSD) formulation development of BCS Class II and IV molecules.

At BDD, Darren leverages his commercial and scientific expertise to address complex drug development challenges for BDD’s partners and clients.